{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T07:16:55Z","timestamp":1793776615823,"version":"4.6.1"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T00:00:00Z","timestamp":1694736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T00:00:00Z","timestamp":1694736000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","award":["2021SGR00042"],"award-info":[{"award-number":["2021SGR00042"]}],"id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","award":["2021SGR00042"],"award-info":[{"award-number":["2021SGR00042"]}],"id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","award":["2021SGR00776"],"award-info":[{"award-number":["2021SGR00776"]}],"id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["FIS PI22\/00171"],"award-info":[{"award-number":["FIS PI22\/00171"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["FIS PI22\/00171"],"award-info":[{"award-number":["FIS PI22\/00171"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["FIS PI16\/00112"],"award-info":[{"award-number":["FIS PI16\/00112"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["FIS PI22\/00171"],"award-info":[{"award-number":["FIS PI22\/00171"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["FIS PI22\/00171"],"award-info":[{"award-number":["FIS PI22\/00171"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010434","name":"\u201cla Caixa\u201d Foundation","doi-asserted-by":"publisher","award":["LCF\/BQ\/DI21\/11860060"],"award-info":[{"award-number":["LCF\/BQ\/DI21\/11860060"]}],"id":[{"id":"10.13039\/100010434","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007406","name":"Fundaci\u00f3n BBVA","doi-asserted-by":"publisher","award":["EIC21-1-977"],"award-info":[{"award-number":["EIC21-1-977"]}],"id":[{"id":"10.13039\/100007406","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007406","name":"Fundaci\u00f3n BBVA","doi-asserted-by":"publisher","award":["EIC21-1-977"],"award-info":[{"award-number":["EIC21-1-977"]}],"id":[{"id":"10.13039\/100007406","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007406","name":"Fundaci\u00f3n BBVA","doi-asserted-by":"publisher","award":["EIC21-1-977"],"award-info":[{"award-number":["EIC21-1-977"]}],"id":[{"id":"10.13039\/100007406","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment and can result in complete remissions even at advanced stages of the disease. However, only a small fraction of patients respond to the treatment. To better understand which factors drive clinical benefit, we have generated whole exome and RNA sequencing data from 27 advanced urothelial carcinoma patients treated with anti-PD-(L)1 monoclonal antibodies. We assessed the influence on the response of non-synonymous mutations (tumor mutational burden or TMB), clonal and subclonal mutations, neoantigen load and various gene expression markers. We found that although TMB is significantly associated with response, this effect can be mostly explained by clonal mutations, present in all cancer cells. This trend was validated in an additional cohort. Additionally, we found that responders with few clonal mutations had abnormally high levels of T and B cell immune markers, suggesting that a high immune cell infiltration signature could be a better predictive biomarker for this subset of patients. Our results support the idea that highly clonal cancers are more likely to respond to ICI and suggest that non-additive effects of different signatures should be considered for predictive models.<\/jats:p>","DOI":"10.1038\/s41598-023-42495-2","type":"journal-article","created":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T06:04:39Z","timestamp":1694757879000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["The impact of mutational clonality in predicting the response to immune checkpoint inhibitors in advanced urothelial cancer"],"prefix":"10.1038","volume":"13","author":[{"given":"Lilian Marie","family":"Boll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00falia","family":"Perera-Bel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejo","family":"Rodriguez-Vida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriol","family":"Arp\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Rovira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00faria","family":"Juanpere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"V\u00e1zquez Montes de Oca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Hern\u00e1ndez-Llodr\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Lloreta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Mar","family":"Alb\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquim","family":"Bellmunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,15]]},"reference":[{"key":"42495_CR1","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.eururo.2016.06.010","volume":"71","author":"S Antoni","year":"2017","unstructured":"Antoni, S. et al. Bladder cancer incidence and mortality: A global overview and recent trends. Eur. Urol. 71, 96\u2013108 (2017).","journal-title":"Eur. Urol."},{"key":"42495_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13073-019-0666-2","volume":"11","author":"MM Richters","year":"2019","unstructured":"Richters, M. M. et al. Best practices for bioinformatic characterization of neoantigens for clinical utility. Genome Med. 11, 1\u201321 (2019).","journal-title":"Genome Med."},{"key":"42495_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-20314-w","volume":"12","author":"K Li","year":"2021","unstructured":"Li, K. et al. PD-1 suppresses TCR-CD8 cooperativity during T-cell antigen recognition. Nat. Commun. 12, 1\u201313 (2021).","journal-title":"Nat. Commun."},{"key":"42495_CR4","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1002\/cncr.22588","volume":"109","author":"BA Inman","year":"2007","unstructured":"Inman, B. A. et al. PD-L1 (B7\u2013H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: Associations with localized stage progression. Cancer 109, 1499\u20131505 (2007).","journal-title":"Cancer"},{"key":"42495_CR5","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt, J. et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N. Engl. J. Med. 376, 1015\u20131026 (2017).","journal-title":"N. Engl. J. Med."},{"key":"42495_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1001\/jamanetworkopen.2019.2535","volume":"2","author":"A Haslam","year":"2019","unstructured":"Haslam, A. & Prasad, V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw. Open 2, 25 (2019).","journal-title":"JAMA Netw. Open"},{"key":"42495_CR7","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3390\/cancers13010131","volume":"13","author":"A Lopez-Beltran","year":"2021","unstructured":"Lopez-Beltran, A. et al. Immune checkpoint inhibitors for the treatment of bladder cancer. Cancers 13, 131 (2021).","journal-title":"Cancers"},{"key":"42495_CR8","first-page":"25","volume":"14","author":"A Snyder","year":"2017","unstructured":"Snyder, A. et al. Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis. PLoS\u00a0Med. 14, 25 (2017).","journal-title":"PLoS\u00a0Med."},{"key":"42495_CR9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1042\/BSR20194337","volume":"40","author":"J Lv","year":"2020","unstructured":"Lv, J., Zhu, Y., Ji, A., Zhang, Q. & Liao, G. Mining TCGA database for tumor mutation burden and their clinical significance in bladder cancer. Biosci. Rep. 40, 25 (2020).","journal-title":"Biosci. Rep."},{"key":"42495_CR10","first-page":"25","volume":"6","author":"RP Graf","year":"2022","unstructured":"Graf, R. P. et al. Tumor mutational burden as a predictor of first-line immune checkpoint inhibitor versus carboplatin benefit in cisplatin-unfit patients with urothelial carcinoma. JCO Precis. Oncol. 6, 25 (2022).","journal-title":"JCO Precis. Oncol."},{"key":"42495_CR11","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.annonc.2021.02.006","volume":"32","author":"DJ McGrail","year":"2021","unstructured":"McGrail, D. J. et al. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann. Oncol. 32, 661\u2013672 (2021).","journal-title":"Ann. Oncol."},{"key":"42495_CR12","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","volume":"51","author":"RM Samstein","year":"2019","unstructured":"Samstein, R. M. et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat. Genet. 51, 202\u2013206 (2019).","journal-title":"Nat. Genet."},{"key":"42495_CR13","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1158\/2159-8290.CD-20-0522","volume":"10","author":"D Sha","year":"2020","unstructured":"Sha, D. et al. Tumor mutational burden as a predictive biomarker in solid tumors. Cancer Discov. 10, 1808\u20131825 (2020).","journal-title":"Cancer Discov."},{"key":"42495_CR14","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1126\/science.aaf2288","volume":"352","author":"E Str\u00f8nen","year":"2016","unstructured":"Str\u00f8nen, E. et al. Targeting of cancer neoantigens with donor-derived T cell receptor repertoires. Science 352, 1337\u20131341 (2016).","journal-title":"Science"},{"issue":"351","key":"42495_CR15","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","volume":"1979","author":"N McGranahan","year":"2016","unstructured":"McGranahan, N. et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 1979(351), 1463\u20131469 (2016).","journal-title":"Science"},{"key":"42495_CR16","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.cell.2019.08.032","volume":"179","author":"Y Wolf","year":"2019","unstructured":"Wolf, Y. et al. UVB-induced tumor heterogeneity diminishes immune response in melanoma. Cell 179, 219-235.e21 (2019).","journal-title":"Cell"},{"key":"42495_CR17","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1038\/s41588-018-0200-2","volume":"50","author":"D Miao","year":"2018","unstructured":"Miao, D. et al. Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nat. Genet. 50, 1271\u20131281 (2018).","journal-title":"Nat. Genet."},{"key":"42495_CR18","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.cell.2021.01.002","volume":"184","author":"K Litchfield","year":"2021","unstructured":"Litchfield, K. et al. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell 184, 596-614.e14 (2021).","journal-title":"Cell"},{"key":"42495_CR19","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson, A. G. et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 171, 540-556.e25 (2017).","journal-title":"Cell"},{"key":"42495_CR20","doi-asserted-by":"publisher","first-page":"4514","DOI":"10.1158\/1078-0432.CCR-14-1215","volume":"21","author":"J Kim","year":"2015","unstructured":"Kim, J. et al. Invasive bladder cancer: Genomic insights and therapeutic promise. Clin. Cancer Res. 21, 4514\u20134524 (2015).","journal-title":"Clin. Cancer Res."},{"key":"42495_CR21","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1038\/ng.2702","volume":"45","author":"SA Roberts","year":"2013","unstructured":"Roberts, S. A. et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat. Genet. 45, 970\u2013976 (2013).","journal-title":"Nat. Genet."},{"key":"42495_CR22","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1101\/gr.239244.118","volume":"28","author":"A Mayakonda","year":"2018","unstructured":"Mayakonda, A., Lin, D. C., Assenov, Y., Plass, C. & Koeffler, H. P. Maftools: Efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 28, 1747\u20131756 (2018).","journal-title":"Genome Res."},{"key":"42495_CR23","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nature12965","volume":"507","author":"JN Weinstein","year":"2014","unstructured":"Weinstein, J. N. et al. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507, 315\u2013322 (2014).","journal-title":"Nature"},{"key":"42495_CR24","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1016\/j.celrep.2014.04.038","volume":"7","author":"I Nordentoft","year":"2014","unstructured":"Nordentoft, I. et al. Mutational context and diverse clonal development in early and late bladder cancer. Cell. Rep. 7, 1649\u20131663 (2014).","journal-title":"Cell. Rep."},{"key":"42495_CR25","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.ydbio.2013.12.028","volume":"386","author":"M B\u00f6ck","year":"2014","unstructured":"B\u00f6ck, M. et al. Identification of ELF3 as an early transcriptional regulator of human urothelium. Dev. Biol. 386, 321\u2013330 (2014).","journal-title":"Dev. Biol."},{"key":"42495_CR26","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nature12634","volume":"502","author":"C Kandoth","year":"2013","unstructured":"Kandoth, C. et al. Mutational landscape and significance across 12 major cancer types. Nature 502, 333\u2013339 (2013).","journal-title":"Nature"},{"key":"42495_CR27","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/ng.907","volume":"43","author":"Y Gui","year":"2011","unstructured":"Gui, Y. et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat. Genet. 43, 875\u2013878 (2011).","journal-title":"Nat. Genet."},{"key":"42495_CR28","first-page":"3593","volume":"362","author":"R Cristescu","year":"2018","unstructured":"Cristescu, R. et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science (1979) 362, 3593 (2018).","journal-title":"Science (1979)"},{"key":"42495_CR29","first-page":"1","volume":"13","author":"ZZ Gajic","year":"2022","unstructured":"Gajic, Z. Z., Deshpande, A., Legut, M., Imieli\u0144ski, M. & Sanjana, N. E. Recurrent somatic mutations as predictors of immunotherapy response. Nat. Commun. 13, 1\u201311 (2022).","journal-title":"Nat. Commun."},{"key":"42495_CR30","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","volume":"387","author":"L Fehrenbacher","year":"2016","unstructured":"Fehrenbacher, L. et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): A multicentre, open-label, phase 2 randomised controlled trial. Lancet 387, 1837\u20131846 (2016).","journal-title":"Lancet"},{"key":"42495_CR31","doi-asserted-by":"publisher","first-page":"25","DOI":"10.4049\/jimmunol.1700893","volume":"199","author":"V Jurtz","year":"2017","unstructured":"Jurtz, V. et al. NetMHCpan 4.0: Improved peptide-MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data. J. Immunol. 199, 25 (2017).","journal-title":"J. Immunol."},{"key":"42495_CR32","doi-asserted-by":"publisher","first-page":"3310","DOI":"10.1093\/bioinformatics\/btu548","volume":"30","author":"A Szolek","year":"2014","unstructured":"Szolek, A. et al. OptiType: Precision HLA typing from next-generation sequencing data. Bioinformatics 30, 3310\u20133316 (2014).","journal-title":"Bioinformatics"},{"key":"42495_CR33","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1002\/eji.201141774","volume":"42","author":"M Harndahl","year":"2012","unstructured":"Harndahl, M. et al. Peptide-MHC class I stability is a better predictor than peptide affinity of CTL immunogenicity. Eur. J. Immunol. 42, 1405\u20131416 (2012).","journal-title":"Eur. J. Immunol."},{"key":"42495_CR34","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.4049\/jimmunol.1600582","volume":"197","author":"M Rasmussen","year":"2016","unstructured":"Rasmussen, M. et al. Pan-specific prediction of peptide\u2013MHC class I complex stability, a correlate of T cell immunogenicity. J. Immunol. 197, 1517\u20131524 (2016).","journal-title":"J. Immunol."},{"key":"42495_CR35","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1084\/jem.20141308","volume":"211","author":"F Duan","year":"2014","unstructured":"Duan, F. et al. Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity. J. Exp. Med. 211, 2231\u20132248 (2014).","journal-title":"J. Exp. Med."},{"key":"42495_CR36","doi-asserted-by":"publisher","first-page":"E1754","DOI":"10.1073\/pnas.1500973112","volume":"112","author":"D Chowell","year":"2015","unstructured":"Chowell, D. et al. TCR contact residue hydrophobicity is a hallmark of immunogenic CD8+ T cell epitopes. Proc. Natl. Acad. Sci. USA 112, E1754\u2013E1762 (2015).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"42495_CR37","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1084\/jem.20190179","volume":"217","author":"A-HH Capietto","year":"2020","unstructured":"Capietto, A.-H.H. et al. Mutation position is an important determinant for predicting cancer neoantigens. J. Exp. Med. 217, 25 (2020).","journal-title":"J. Exp. Med."},{"key":"42495_CR38","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/2162402X.2018.1550341","volume":"8","author":"A Boichard","year":"2019","unstructured":"Boichard, A. et al. APOBEC-related mutagenesis and neo-peptide hydrophobicity: Implications for response to immunotherapy. Oncoimmunology 8, 25 (2019).","journal-title":"Oncoimmunology"},{"key":"42495_CR39","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan, S. et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544\u2013548 (2018).","journal-title":"Nature"},{"key":"42495_CR40","doi-asserted-by":"publisher","first-page":"4476","DOI":"10.1158\/0008-5472.CAN-20-0977","volume":"80","author":"J Bellmunt","year":"2020","unstructured":"Bellmunt, J. et al. Genomic predictors of good outcome, recurrence, or progression in high-grade T1 non-muscle-invasive bladder cancer. Cancer Res. 80, 4476\u20134486 (2020).","journal-title":"Cancer Res."},{"key":"42495_CR41","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13073-020-00781-y","volume":"12","author":"MJ Shi","year":"2020","unstructured":"Shi, M. J. et al. Identification of new driver and passenger mutations within APOBEC-induced hotspot mutations in bladder cancer. Genome Med. 12, 25 (2020).","journal-title":"Genome Med."},{"key":"42495_CR42","doi-asserted-by":"publisher","first-page":"4537","DOI":"10.18632\/oncotarget.23344","volume":"9","author":"AP Glaser","year":"2018","unstructured":"Glaser, A. P. et al. APOBEC-mediated mutagenesis in urothelial carcinoma is associated with improved survival, mutations in DNA damage response genes, and immune response. Oncotarget 9, 4537 (2018).","journal-title":"Oncotarget"},{"key":"42495_CR43","doi-asserted-by":"publisher","first-page":"5120","DOI":"10.1158\/1078-0432.CCR-19-4162","volume":"26","author":"MD Galsky","year":"2020","unstructured":"Galsky, M. D. et al. Nivolumab in patients with advanced platinum-resistant urothelial carcinoma: Efficacy, safety, and biomarker analyses with extended follow-up from CheckMate 275. Clin. Cancer Res. 26, 5120\u20135128 (2020).","journal-title":"Clin. Cancer Res."},{"key":"42495_CR44","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1158\/2326-6066.CIR-17-0559","volume":"6","author":"AJ Rech","year":"2018","unstructured":"Rech, A. J. et al. Tumor immunity and survival as a function of alternative neopeptides in human cancer. Cancer Immunol. Res. 6, 276 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"42495_CR45","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.cell.2017.09.050","volume":"171","author":"R Marty","year":"2017","unstructured":"Marty, R. et al. MHC-I genotype restricts the oncogenic mutational landscape. Cell 171, 1272-1283.e15 (2017).","journal-title":"Cell"},{"key":"42495_CR46","doi-asserted-by":"publisher","first-page":"3967","DOI":"10.1073\/pnas.0611618104","volume":"104","author":"P Sharma","year":"2007","unstructured":"Sharma, P. et al. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc. Natl. Acad. Sci. USA 104, 3967 (2007).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"42495_CR47","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nri3789","volume":"15","author":"T Kitamura","year":"2015","unstructured":"Kitamura, T., Qian, B. Z. & Pollard, J. W. Immune cell promotion of metastasis. Nat. Rev. Immunol. 15, 73\u201386 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"42495_CR48","first-page":"5","volume":"2","author":"N Guti\u00e9rrez-Melo","year":"2023","unstructured":"Guti\u00e9rrez-Melo, N. & Baumjohann, D. T follicular helper cells in cancer. Trends Cancer 2, 5 (2023).","journal-title":"Trends Cancer"},{"key":"42495_CR49","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1038\/s41590-022-01274-3","volume":"23","author":"RS Herati","year":"2022","unstructured":"Herati, R. S. et al. PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine. Nat. Immunol. 23, 1183 (2022).","journal-title":"Nat. Immunol."},{"key":"42495_CR50","doi-asserted-by":"publisher","first-page":"6075","DOI":"10.1158\/1078-0432.CCR-21-0697","volume":"27","author":"SS Kim","year":"2021","unstructured":"Kim, S. S. et al. Role of B cells in responses to checkpoint blockade immunotherapy and overall survival of cancer patients. Clin. Cancer Res. 27, 6075 (2021).","journal-title":"Clin. Cancer Res."},{"key":"42495_CR51","first-page":"25","volume":"7","author":"E Schaafsma","year":"2021","unstructured":"Schaafsma, E., Jiang, C. & Cheng, C. B cell infiltration is highly associated with prognosis and an immune-infiltrated tumor microenvironment in neuroblastoma. J. Cancer Metastasis Treat. 7, 25 (2021).","journal-title":"J. Cancer Metastasis Treat."},{"key":"42495_CR52","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","volume":"577","author":"BA Helmink","year":"2020","unstructured":"Helmink, B. A. et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577, 549\u2013555 (2020).","journal-title":"Nature"},{"key":"42495_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-019-0613-1","volume":"7","author":"W Damsky","year":"2019","unstructured":"Damsky, W. et al. B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors. J. Immunother. Cancer 7, 1\u20137 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"42495_CR54","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S1470-2045(17)30516-8","volume":"18","author":"S Turajlic","year":"2017","unstructured":"Turajlic, S. et al. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: A pan-cancer analysis. Lancet Oncol. 18, 1009\u20131021 (2017).","journal-title":"Lancet Oncol."},{"key":"42495_CR55","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41586-019-1671-8","volume":"574","author":"E Alspach","year":"2019","unstructured":"Alspach, E. et al. MHC-II neoantigens shape tumour immunity and response to immunotherapy. Nature 574, 696\u2013701 (2019).","journal-title":"Nature"},{"key":"42495_CR56","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3389\/fcell.2022.757137","volume":"10","author":"R Yi","year":"2022","unstructured":"Yi, R. et al. MHC-II signature correlates with anti-tumor immunity and predicts anti-PD-L1 response of bladder cancer. Front. Cell Dev. Biol. 10, 25 (2022).","journal-title":"Front. Cell Dev. Biol."},{"key":"42495_CR57","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.cels.2020.06.010","volume":"11","author":"TJ O\u2019Donnell","year":"2020","unstructured":"O\u2019Donnell, T. J., Rubinsteyn, A. & Laserson, U. MHCflurry 2.0: Improved pan-allele prediction of mhc class i-presented peptides by incorporating antigen processing. Cell Syst. 11, 42\u2013487 (2020).","journal-title":"Cell Syst."},{"key":"42495_CR58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0170632","author":"A Esteve-Codina","year":"2017","unstructured":"Esteve-Codina, A. et al. A comparison of RNA-Seq results from paired formalin-fixed paraffin-embedded and fresh-frozen glioblastoma tissue samples. PLoS\u00a0One https:\/\/doi.org\/10.1371\/journal.pone.0170632 (2017).","journal-title":"PLoS\u00a0One"},{"key":"42495_CR59","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1007\/s00268-015-2942-7","volume":"39","author":"YK Kim","year":"2015","unstructured":"Kim, Y. K., Han, H. S., Yoon, Y. S., Cho, J. Y. & Lee, W. Laparoscopic approach for right-sided intrahepatic duct stones: A comparative study of laparoscopic versus open treatment. World J. Surg. 39, 1224\u20131230 (2015).","journal-title":"World J. Surg."},{"key":"42495_CR60","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41592-020-01013-2","volume":"18","author":"M Tarabichi","year":"2021","unstructured":"Tarabichi, M. et al. A practical guide to cancer subclonal reconstruction from DNA sequencing. Nat. Methods 18, 144\u2013155 (2021).","journal-title":"Nat. Methods"},{"key":"42495_CR61","doi-asserted-by":"publisher","first-page":"16910","DOI":"10.1073\/pnas.1009843107","volume":"107","author":"P Van Loo","year":"2010","unstructured":"Van Loo, P. et al. Allele-specific copy number analysis of tumors. Proc. Natl. Acad. Sci. USA 107, 16910\u201316915 (2010).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"42495_CR62","doi-asserted-by":"publisher","first-page":"63","DOI":"10.12688\/f1000research.16665.2","volume":"9","author":"M Garcia","year":"2020","unstructured":"Garcia, M. et al. Sarek: A portable workflow for whole-genome sequencing analysis of germline and somatic variants. F1000Res 9, 63 (2020).","journal-title":"F1000Res"},{"key":"42495_CR63","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41587-020-0439-x","volume":"38","author":"PA Ewels","year":"2020","unstructured":"Ewels, P. A. et al. The nf-core framework for community-curated bioinformatics pipelines. Nat. Biotechnol. 38, 276\u2013278. https:\/\/doi.org\/10.1038\/s41587-020-0439-x (2020).","journal-title":"Nat. Biotechnol."},{"key":"42495_CR64","doi-asserted-by":"publisher","first-page":"W449","DOI":"10.1093\/nar\/gkaa379","volume":"48","author":"B Reynisson","year":"2020","unstructured":"Reynisson, B. et al. NetMHCpan-4.1 and NetMHCIIpan-4.0: Improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Res. 48, W449\u2013W454 (2020).","journal-title":"Nucleic Acids Res."},{"key":"42495_CR65","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.cell.2020.09.015","volume":"183","author":"DK Wells","year":"2020","unstructured":"Wells, D. K. et al. Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction. Cell 183, 818-834.e13 (2020).","journal-title":"Cell"},{"key":"42495_CR66","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1093\/annonc\/mdx687","volume":"29","author":"E Ghorani","year":"2018","unstructured":"Ghorani, E. et al. Differential binding affinity of mutated peptides for MHC class I is a predictor of survival in advanced lung cancer and melanoma. Ann. Oncol. 29, 271\u2013279 (2018).","journal-title":"Ann. Oncol."},{"key":"42495_CR67","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: Ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"42495_CR68","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","volume":"30","author":"Y Liao","year":"2014","unstructured":"Liao, Y., Smyth, G. K. & Shi, W. featureCounts: An efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923\u2013930 (2014).","journal-title":"Bioinformatics"},{"key":"42495_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/gb-2010-11-3-r25","volume":"11","author":"MD Robinson","year":"2010","unstructured":"Robinson, M. D. & Oshlack, A. A scaling normalization method for differential expression analysis of RNA-seq data. Genome Biol. 11, 1\u20139 (2010).","journal-title":"Genome Biol."},{"key":"42495_CR70","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: A bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139\u2013140 (2010).","journal-title":"Bioinformatics"},{"key":"42495_CR71","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"42495_CR72","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu, G., Wang, L. G., Han, Y. & He, Q. Y. ClusterProfiler: An R package for comparing biological themes among gene clusters. OMICS 16, 284\u2013287 (2012).","journal-title":"OMICS"},{"key":"42495_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann, S., Castelo, R. & Guinney, J. GSVA: Gene set variation analysis for microarray and RNA-Seq data. BMC Bioinform. 14, 1\u201315 (2013).","journal-title":"BMC Bioinform."},{"key":"42495_CR74","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","volume":"37","author":"AM Newman","year":"2019","unstructured":"Newman, A. M. et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat. Biotechnol. 37, 773\u2013782 (2019).","journal-title":"Nat. Biotechnol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-42495-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-42495-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-42495-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T06:21:41Z","timestamp":1700461301000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-42495-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,15]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["42495"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-42495-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2782434\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,15]]},"assertion":[{"value":"5 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15287"}}